Please assess the completion status of the following clinical trial:

Trial Title: Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* best corrected visual acuity of 5-65, inclusive, in study eye~* presence of choroid neovascularization secondary to AMD~* persistent edema despite at least 3 previous intravitreal anti-VEGF injections in the past 5 months~Exclusion Criteria:~* greater than 100 micron decrease in central subfield thickness on Optical Coherence Topography (OCT) since last standard of care visit~* history of major ophthalmic surgery in the study eye in the past 3 months~* history of significant ocular disease or condition other than exudative AMD that may confound results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sirolimus (Type: EXPERIMENTAL): Intravitreal Sirolimus
- Standard of Care intravitreal anti-VEGF (Type: ACTIVE_COMPARATOR): anti-VEGF intravitreal injections

Based on this trial design, predict the completion outcome and termination type (if applicable).